All In Biotech

Drug Trial Radar · NCT06927999

An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

An Outpatient, Randomized, Double-Blinded, Placebo-Controlled, Cross-Over Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Jul 9, 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
ARS Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods. Subjects enrolled will have CSU with a history of moderate to severe acute exacerbations (or flares).

Conditions

  • Urticaria Chronic

Interventions

  • PlaceboDrug

    Placebo solution nasal spray containing no active drug

  • 0.5 mg epinephrineDrug

    0.5 mg epinephrine per spray

  • 1 mg epinephrineDrug

    1 mg epinephrine per spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determine the effect of ARS-2 (0.5 mg or 1 mg) versus placebo on itchTime frame: 12 months

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Endeavor Health Clinical Trials Center

    Glenview, Illinois · Recruiting

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio · Recruiting

  • Institute of Allergology IFA Charité - Campus Benjamin Franklin | Hindenburgdamm 30

    Berlin, Germany · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.